Catalog No.:AA000QTG

1260612-13-2 | (S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one

Name: Name:(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one
Brand: AABLOCKS
SKU: AA000QTG
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

≥98%

in stock

$55.00 $38.00

- +

5mg

≥98%

in stock

$238.00 $166.00

- +

10mg

≥98%

in stock

$418.00 $292.00

- +

50mg

95%

in stock

$681.00 $477.00

- +

250mg

95%

in stock

$1,939.00 $1,358.00

- +

Technical Information
Properties
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Literature

Technical Information

Catalog Number:

AA000QTG

Chemical Name:

(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one

CAS Number:

1260612-13-2

Molecular Formula:

C19H22N4O3

Molecular Weight:

354.4030

MDL Number:

MFCD27987912

SMILES:

C[C@H]1Cc2c(N1C(=O)Cc1nc(cc(=O)[nH]1)N1CCOCC1)cccc2

Properties

Computed Properties

Complexity:

639

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

0.9

Literature

Title: Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Journal: Journal of medicinal chemistry 20140213

Title: Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.

Title: Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS